Recursion Pharmaceuticals (RXRX) Surges 14% Ahead of Earnings

We recently published 10 Big Names Beating Wall Street at its Own Game. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the best performers on Monday.

Recursion Pharmaceuticals soared by 13.99 percent on Monday to close at $6.68 apiece as investors resorted to bargain-hunting following a two-day drop, while repositioning portfolios ahead of earnings release.

Based on its historical reporting dates, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) will announce the results of its third quarter financial and operating highlights in the first week of November 2025.

To recall, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) incurred a 76 percent higher net loss in the second quarter of the year, at $171.9 million, versus the $97.5 million in the same period last year.

Revenues, on the other hand, increased by 33 percent to $19.2 million as compared with the $14.4 million year-on-year, with the bulk consisting primarily of revenues from collaboration agreements.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a clinical stage biotechnology company leveraging sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry. It is among the few companies that technology giant Nvidia Corp. directly invested in.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.